Abiogen Pharma And Oryx Pharmaceuticals Inc. : A License Agreement For Disodium Clodronate 
10/19/2005 5:09:13 PM

PISA, Italy--(BUSINESS WIRE)--June 20, 2005--The license agreement grants Oryx the exclusive license to market the speciality Clasteon (R) (the bisphosphonate Disodium Clodronate) in Canada. Oryx Pharmaceutical Inc. launched Clasteon (R) 400 mg capsules in May 2004 and currently purchases the finished product from Abiogen which manufactures it at its new facility located in the industrial area of Pisa.